update Stryker Hip Settlement News: Stryker Agrees to Settle Four NJ Lawsuits

Medical device manufacturer Stryker Corporation has agreed to settle four ABG II and Rejuvenate hip implant lawsuits in New Jersey, according to court documents. The Rottenstein Law Group LLP notes that this Dec. 16 order follows October news that Stryker planned to set aside possibly $1 billion for ABG II and Rejuvenate-related litigation.

The parties settled the lawsuits for undisclosed sums, according to court documents (In re: Stryker Rejuvenate HipStem and the ABG II Modular Hip Stem Litigation; MCL-296, Bergen County Superior Court, New Jersey).

Stryker announced in October that it will set aside between $700 million and more than $1 billion for metal-on-metal hip-related litigation, according to an Oct. 23 Wall Street Journal report.

“Settlements are one way for plaintiffs to be made whole again following complications with their metal-on-metal hip implants that cause injuries,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “With a settlement, there is a certain outcome for both sides, as opposed to going to trial, which is unpredictable.”

There are about 400 Stryker lawsuits pending in a consolidation of cases in U.S. District Court in Minnesota called a “multidistrict litigation” and more than 500 in a New Jersey consolidation called a “multicounty litigation.”

The Stryker lawsuits involve two of the company’s metal-on-metal hip implant products, the Rejuvenate and the ABG II, both recalled in July 2012. Claims against Stryker range from metal poisoning to device failure, according to court document. The U.S. Food and Drug Administration supports claimants’ allegations.

Stryker hip injury claims are part of a larger problem with metal-on-metal hip implants, Rottenstein said. DePuyOrthopaedics recently agreed to a multibillion-dollar settlement involving 8,000 ASR hip implant lawsuits in federal and state courts, she added.

“Of course, DePuy’s agreement is on a much larger scale, but there is always the possibility of Stryker taking a similar approach,” Rottenstein said.


Join the Discussion

Please note: Comments are encouraged in order to permit visitors to discuss relevant topics. Comments are moderated and might be edited by RLG before being published.

Comments should not be used to ask questions of RLG’s lawyers; if you want to speak with a lawyer, please fill out this contact form or call 1 (888) 976-8529. *Your name and email address will not be published.



RLG encourages you to reproduce our original content—on your own web site; in emails to your friends and family; in blogs, posts, and tweets, etc.—but we ask that you please attribute whatever you use to us, and, whenever possible, provide a link to the page where you first found the material. That way, whoever reads your excerpt might read more informative material of interest at one of RLG's sites.
You’ve taken enough. We'll take it from here. Click here to contact us now.